Evidence map›Paper›PMID 42412359›Full record

ArticleClinical journal of gastroenterology2026

Long-term disease control of GP2-NTRK1 fusion-positive pancreatic adenocarcinoma with liver metastases using sequential tyrosine receptor kinase inhibitors.

Sho Tazuma, Takeshi Sudo, Kenta Baba, Takashi Onoe, Tatsuaki Sumiyoshi, Kazuya Kuraoka, Kenichiro Uemura, Shinya Takahashi, Hirotaka Tashiro, Yosuke Shimizu

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Clinical journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sho TazumaDepartment of Surgery, Graduate School of Biomedical and Health Science, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. shtazuma@hiroshima-u.ac.jp.ORCID http://orcid.org/0000-0002-3419-8444
Takeshi SudoDepartment of Surgery, Kure Medical Center/Chugoku Cancer Center, National Hospital Organization, 3-1, Kure, Hiroshima, 737-0023, Japan.
Kenta BabaDepartment of Surgery, Kure Medical Center/Chugoku Cancer Center, National Hospital Organization, 3-1, Kure, Hiroshima, 737-0023, Japan.
Takashi OnoeDepartment of Surgery, Kure Medical Center/Chugoku Cancer Center, National Hospital Organization, 3-1, Kure, Hiroshima, 737-0023, Japan.
Tatsuaki SumiyoshiDepartment of Surgery, Graduate School of Biomedical and Health Science, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
Kazuya KuraokaDepartment of Diagnostic Pathology, Kure Medical Center/Chugoku Cancer Center, National Hospital Organization, Kure, Hiroshima, 3-1, 737-0023, Japan.
Kenichiro UemuraDepartment of Surgery, Graduate School of Biomedical and Health Science, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
Shinya TakahashiDepartment of Surgery, Graduate School of Biomedical and Health Science, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
Hirotaka TashiroDepartment of Surgery, Kure Medical Center/Chugoku Cancer Center, National Hospital Organization, 3-1, Kure, Hiroshima, 737-0023, Japan.
Yosuke ShimizuDepartment of Surgery, Kure Medical Center/Chugoku Cancer Center, National Hospital Organization, 3-1, Kure, Hiroshima, 737-0023, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report an extremely rare case of GP2-NTRK1 fusion-positive pancreatic ductal adenocarcinoma (PDAC) with liver metastases in a 78 year-old woman. PDAC is an aggressive cancer that presents with locally advanced or metastatic disease in more than 50% of patients at the time of diagnosis. This is the first case of GP2-NTRK1 fusion-positive PDAC that was successfully treated with gemcitabine and nab-paclitaxel followed by entrectinib and larotrectinib, which resulted in long-term survival of more than 54 months from diagnosis and 34 months from initiation of TRK inhibitor therapy.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Pancreatic DuctalLiver NeoplasmsPancreatic NeoplasmsProtein Kinase InhibitorsAdenocarcinomaAgedAlbuminsBenzamidesDeoxycytidineFemaleGemcitabineHumansIndazolesPaclitaxelPyrazoles130-nm albumin-bound paclitaxelAlbuminsBenzamidesDeoxycytidineentrectinibGemcitabineIndazoleslarotrectinibPaclitaxelProtein Kinase InhibitorsPyrazolesPyrimidinesReceptor, trkATyrosine Kinase InhibitorsEntrectinibLarotrectinibNeurotrophic tyrosine receptor kinase gene fusionPancreatic ductal adenocarcinoma

Identifiers

PMID42412359

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.